DEFA14A: Masimo Eyes 30% Operating Margin Within Five Years Amidst Consumer Business Separation and Shareholder Activism

Masimo discusses its healthcare business performance, consumer business separation plans, and ongoing proxy fight with Politan Capital in a recent Goldman Sachs conference.

Summary

• Masimo is experiencing strong performance in its core healthcare business, driven by market share gains and innovative technologies.
• The company is targeting a 30% operating margin within five years, with potential for 40%.
• Masimo is considering separating its consumer business through a spin-off or joint venture, with a decision expected by the end of June.
• A potential joint venture offer is attractive, possibly adding $0.60 per share to earnings and significantly reducing debt.
• The company is facing a proxy fight with Politan Capital, with concerns raised about the motivations and truthfulness of a Politan-appointed board member.
• Masimo is focused on debt paydown, tuck-in acquisitions, and opportunistic share buybacks for capital allocation.
• The company is excited about upcoming product launches and innovations in hospital automation, telemonitoring, and opioid addiction solutions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong performance of the healthcare business, potential for a lucrative joint venture, and focus on innovation. However, the ongoing proxy fight and uncertainties surrounding the consumer business separation temper the overall outlook.

Positives

• Strong performance in the core healthcare business with increasing market share.
• Targeting significant operating margin improvement to 30% within five years.
• Potential for a highly accretive joint venture for the consumer business.
• Innovation pipeline with new products and solutions for hospital automation, telemonitoring, and opioid addiction.
• Focus on debt reduction and disciplined capital allocation.

Negatives

• Ongoing proxy fight with Politan Capital and concerns about a disruptive board member.
• Potential distraction and costs associated with the proxy contest.
• Uncertainty surrounding the final structure and timing of the consumer business separation.

Risks

• Uncertainties regarding the separation of Masimo's consumer business.
• Potential actions by Politan in furtherance of its nomination of director candidates.
• Cost and management distraction related to Politan's nomination of director nominees.
• Risks related to forward-looking statements, including market conditions and product development.

Future Outlook

Masimo anticipates continued growth in its healthcare business, driven by innovation and market share gains. The company expects to achieve a 30% operating margin within five years and is exploring strategic options for its consumer business. They are aiming to return to a pattern of meeting, beating, and raising expectations.

Management Comments

• Joe Kiani believes that keeping the healthcare and consumer businesses together is the right thing long term, but understands the desire of majority shareholders to focus on the near term.
• Joe Kiani states that he is committed to doing whatever the majority shareholders want regarding the separation of the consumer business.
• Micah Young notes that sensor inventory levels have stabilized and ordering patterns are back to pre-COVID levels.
• Joe Kiani expresses concerns about the disruptive behavior and lack of candor of a Politan-appointed board member.

Industry Context

The discussion touches on broader industry trends such as hospital inventory levels, the shift towards telehealth and telemonitoring, and the ongoing opioid crisis. Masimo is positioning itself to capitalize on these trends with its innovative technologies and solutions.

Comparison to Industry Standards

• Masimo's measure-through-motion technology is considered the best in the industry, with no competitors having caught up.
• Masimo is the only company with Rainbow technology, offering 12 parameters that can be measured with a sensor.
• Masimo's SafetyNet program for COVID-19 demonstrated a 70% reduction in mortality and saved $11,000 per patient, showcasing the potential of telehealth solutions.
• Masimo's Bridge device is presented as a unique solution for opioid withdrawal symptoms, addressing a critical need in the opioid epidemic.

Stakeholder Impact

• Shareholders: Potential for increased earnings and value creation through strategic initiatives.
• Employees: Uncertainty related to the consumer business separation, but potential for growth and innovation in the healthcare business.
• Customers: Continued access to innovative healthcare solutions and technologies.
• Patients: Improved patient outcomes through advanced monitoring and treatment solutions.

Next Steps

• Finalize the terms of the potential joint venture for the consumer business by the end of June.
• Hold discussions with shareholders to determine their preferred path for the consumer business (spin-off or joint venture).
• Potentially complete the joint venture by mid-August if that path is chosen.
• Continue to develop and launch new products in hospital automation, telemonitoring, and opioid addiction solutions.
• Address the ongoing proxy fight with Politan Capital at the upcoming AGM.

Key Dates

Keywords

Masimo, healthcare, consumer business, separation, Politan, proxy fight, operating margin, innovation, opioid, telemonitoring, hospital automation